<DOC>
	<DOC>NCT02608970</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy subjects</brief_summary>
	<brief_title>Safety and Tolerability Study of BMS-986177 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs and clinical laboratory determinations Body Mass Index (BMI) of 18 to 30 kg/m2 inclusive. BMI = weight (kg)/ [height (m)]2 Females who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and men ages 18 to 55, inclusive Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population Any condition that could affect drug absorption Other protocoldefined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>